(Q43690007)

25 November 2017

Safety of fexofenadine in children treated for seasonal allergic rhinitis (English)

1 reference

25 November 2017

Graft DF

1

1 reference

25 November 2017

Bernstein DI

2

1 reference

25 November 2017

Goldsobel A

3

1 reference

25 November 2017

Meltzer EO

4

1 reference

25 November 2017

Portnoy J

5

1 reference

25 November 2017

Long J

6

1 reference

25 November 2017

1 July 2001

1 reference

Annals of Allergy, Asthma & Immunology

25 November 2017

1 reference

25 November 2017

87

1 reference

25 November 2017

1

1 reference

25 November 2017

22-26

1 reference

Learning impairment and allergic rhinitis.

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

An overview of current pharmacotherapy in perennial rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Sedative effects of antihistamines: safety, performance, learning, and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Cardiovascular safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

The systemic safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

The clinical pharmacology of fexofenadine in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Treatment strategies designed to minimize medical complications of allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962317-4

7 January 2021

10.1016/S1081-1206(10)62317-4

Identifiers

DOI

1 reference

release_4o3vqn7doncnznxof65mftvkge

25 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4o3vqn7doncnznxof65mftvkge

24 November 2022

mapped directly with Wikidata item

1 reference